Search
Erlotinib
go.drugbank.com/drugs/DB00530ApprovedInvestigationalErlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. … Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion
Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsMitomycin
go.drugbank.com/drugs/DB00305ApprovedInvestigational[A193419] Mitomycin's cross-linking activity has resulted in its approval for the treatment of a variety of cancers - the most recent of which is an April 2020 approval for its use in low-grade Upper … [L12867,A193419] It is an alkylating agent that inhibits DNA synthesis (and, at higher concentrations, RNA and protein synthesis) by cross-linking the complementary strands of the DNA double helix.
Potassium Iodide
go.drugbank.com/drugs/DB06715ApprovedInvestigationalSSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyroidectomy.
Mixtures: TL-Folate, RE NataTagatose
go.drugbank.com/drugs/DB04936InvestigationalIt is commonly found in dairy with a similar texture and sweetened capacity to sucrose but with only a third of the calories. It is approved as a food additive as a low calorie sweetener. … Additionally, it is under investigation by Spherix for the treatment of obesity and type II diabetes.
Pilocarpine
go.drugbank.com/drugs/DB01085ApprovedInvestigational[A262036] Pilocarpine is used to treat dry mouth and various ophthalmic conditions, including elevated intraocular pressure and glaucoma. The usage of glaucoma by pilocarpine dates back to 1875. … A naturally occurring alkaloid derived from the _Pilocarpus_ plants, pilocarpine is a muscarinic acetylcholine agonist.
Mixtures: E-pilo-2 Oph Soln, E-pilo-6 Oph SolnCategories: Cholinergic Receptor AgonistLipoic acid
go.drugbank.com/drugs/DB00166ApprovedInvestigationalNutraceuticalA vitamin-like antioxidant.
Products: THIOCTACID 600 TOdesivimab
go.drugbank.com/drugs/DB15900ApprovedInvestigational[A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection. … [A222078] The chief surface target of EBOV particles is the GP<sub>1,2</sub> glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic
Ergocalciferol
go.drugbank.com/drugs/DB00153ApprovedInvestigationalNutraceutical[T577] The production of ergocalciferol was prompted by the identification of dietary deficiency, more specifically vitamin D, as the main causative factor for the development of rickets. … [T580] Ergocalciferol is considered the first vitamin D analog and is differentiated from [cholecalciferol] by the presence of a double bond between C22 and C23 and the presence of a methyl group at
Synonyms: (3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol, (5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-olMixtures: Se-Natal, Swical-energy 3e AgeApraclonidine
go.drugbank.com/drugs/DB00964ApprovedInvestigationalApraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist.
Categories: Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor AgonistsAtoltivimab
go.drugbank.com/drugs/DB15898ApprovedInvestigational[A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection. … [A222078] The chief surface target of EBOV particles is the GP<sub>1,2</sub> glycoprotein, which also appears on the surface of EBOV-infected cells, offering opportunities for both neutralizing and cytotoxic